Anil Vangala

Dr. Anil Vangala is a Senior Lecturer in Pharmaceutics at Kingston University's School of Life Sciences, Pharmacy and Chemistry, Department of Pharmacy, where he has served since 2007. He concurrently acts as Course Leader for MSc Pharmaceutical Science programs (including Management Studies and Professional Placement pathways) and serves as external examiner for Liverpool John Moores University's MSc in Cosmetic Science program.

His academic foundation includes a PhD from Aston University (2006) supervised by Professor Yvonne Perrie, an M.Pharmacy from The Tamil Nadu Dr. M.G.R. Medical University (2000), and a B.Pharmacy from Gulbarga University (1997). He holds a Postgraduate Certificate in Teaching and Learning in Higher Education (2013) and was awarded Senior Fellow of the Higher Education Academy (2020).

Dr. Vangala's research centers on advanced drug delivery systems using lipid and polymer-based particulate carriers for vaccines, therapeutic peptides, and ocular therapeutics. His work spans liposome/niosome formulation for vaccine adjuvants, oral delivery of biologics, and trigger-responsive ophthalmic gels. He leads a multidisciplinary research team investigating nanoparticle systems for cancer therapy, diabetes management, and ocular drug delivery.

His 12 publications from 2004-2023 reveal consistent innovation in pharmaceutics, with recent work focusing on chitosan hydrogels for cancer therapy and non-invasive insulin delivery, while maintaining foundational contributions to vaccine adjuvant systems and ocular drug permeation studies.

His scientific recognition includes:

• Senior Fellow of the Higher Education Academy (2020)

Dr. Vangala actively mentors PhD and master's students while serving as thesis examiner and journal reviewer for leading publications including International Journal of Pharmaceutics. He contributes to academic governance as topical advisory panel member for Pharmaceutics journal (IF: 5.875) and as Race Equality Charter self-assessment team member at Kingston University.

His research team maintains active projects in nanoparticle formulation and drug delivery optimization, with recent focus on polymeric systems for targeted cancer therapy and diabetes management.